An oncologist’s perspective on measuring success in the clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even though cancer center and health system leaders know this deep down, most also find no way better to measure the success of programs and providers than the inscrutable Relative Value Unit, or RVU.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC
Table of Contents

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC

Login